Depending on how long it takes medical venues to review the Hemopurifier data & potentially approve moving forward, we believe clinical efforts could begin in 2H24. AEMD had cash of about $9.1M as of June 25, 2024, to support its efforts, following a recent capital raise. The company also believes it has a sufficient supply of Hemopurifiers for its planned oncology trials. AEMD's focus is on evaluating the device within the oncology space. The company is also maintaining a trial studying the Hemopurifier as a treatment for patients in the ICU with severe Covid and has a publication pending regarding its benefits in organ transplants.
